Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma

Disparities in metastatic renal cell carcinoma (mRCC) outcomes persist in the era of oral anticancer agents (OAAs) and immunotherapies (IOs). We examined variation in the utilization of mRCC systemic therapies among US Medicare beneficiaries from 2015 to 2019. Logistic regression models evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Ryan D, Long, Jessica B, Hassan, Sirad, Wheeler, Stephanie B, Spees, Lisa P, Leapman, Michael S, Hurwitz, Michael E, McManus, Hannah D, Gross, Cary P, Dinan, Michaela A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276895/
https://www.ncbi.nlm.nih.gov/pubmed/37202354
http://dx.doi.org/10.1093/jncics/pkad036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276895/
https://www.ncbi.nlm.nih.gov/pubmed/37202354
http://dx.doi.org/10.1093/jncics/pkad036

Ejemplares similares